The chemical class known as Cryptic Inhibitors encompasses a range of compounds designed to modulate the activity of Cryptic, a protein crucial in the Nodal signaling pathway and embryonic development. These inhibitors are characterized by their ability to influence the signaling pathways and cellular processes in which Cryptic plays a pivotal role. Predominantly, these compounds achieve their function by targeting key components of the TGF-β (Transforming Growth Factor Beta) superfamily pathways, including Nodal, Activins, and BMPs (Bone Morphogenetic Proteins). By interacting with these pathways, Cryptic inhibitors can alter the functional dynamics of Cryptic within cells, modulating its activity in embryonic development, particularly in processes like mesoderm formation, left-right axis establishment, and organogenesis.
The development and functionality of Cryptic inhibitors are grounded in a sophisticated understanding of the protein's role in cell biology. Given Cryptic's involvement in crucial developmental processes and its interactions with significant growth factors and receptors, these inhibitors operate by either disrupting Cryptic's ability to interact with these components or by altering the downstream signaling cascades that Cryptic influences. This is achieved through various molecular actions, such as inhibition of kinase activity, modulation of intracellular signaling molecules, and interference with specific molecular pathways involved in cell differentiation and growth. The diversity of these inhibitors reflects the complexity of Cryptic's role in cellular functions, highlighting the intricate network of molecular interactions and pathways essential for normal embryonic development. In summary, Cryptic inhibitors represent a significant group of compounds that provide valuable insights into the molecular functions of Cryptic. Their ability to modulate key aspects of cellular signaling and development underscores the critical role of Cryptic in these processes. As research tools, these inhibitors facilitate exploration of the myriad functions of Cryptic, enhancing our understanding of cellular communication and developmental biology. This class of inhibitors, therefore, plays a crucial role in advancing our knowledge of the fundamental mechanisms of cellular function and the dynamics of Cryptic in developmental processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 targets the TGF-β receptor. This action could possibly inhibit CFC1 by disrupting TGF-β signaling. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
LY364947 inhibits TGF-β type I receptor kinase. Reducing TGF-β signaling could possibly inhibit CFC1-mediated processes. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A-83-01 inhibits ALK5, ALK7, and ALK4, which are receptors in the TGF-β pathway. This could possibly inhibit CFC1's interaction with these receptors in Nodal signaling. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
RepSox targets the TGF-β type I receptor ALK5. Inhibiting ALK5 could possibly inhibit CFC1's role in TGF-β signaling pathways. | ||||||
SB-505124 | 694433-59-5 | sc-362794 sc-362794A | 10 mg 50 mg | $327.00 $1377.00 | 2 | |
SB-505124 selectively inhibits ALK4, ALK5, and ALK7. This inhibition could possibly inhibit CFC1's involvement in Nodal and TGF-β signaling. | ||||||
LY2157299 | 700874-72-2 | sc-391123 sc-391123A | 5 mg 10 mg | $213.00 $359.00 | 3 | |
LY2157299 inhibits TGF-β receptor I. This could possibly inhibit TGF-β signaling pathways involving CFC1. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
LY2157299 targets TGF-β receptor I. Disrupting TGF-β signaling could possibly inhibit CFC1's functional role in this pathway. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
SD-208 is a TGF-β receptor I kinase inhibitor. Inhibiting this receptor could possibly inhibit TGF-β signaling pathways involving CFC1. | ||||||
DMH-1 | 1206711-16-1 | sc-361171 sc-361171B sc-361171A sc-361171C | 10 mg 25 mg 50 mg 100 mg | $213.00 $318.00 $632.00 $1047.00 | 2 | |
DMH1 is a selective ALK2 inhibitor. Although targeting ALK2, it could possibly influence TGF-β/BMP signaling pathways, potentially inhibiting CFC1. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 inhibits BMP, targeting ALK2 and ALK3 receptors. This could possibly inhibit CFC1's interaction with BMPs in signaling pathways. | ||||||